Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic ...

Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.

Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population. The Food and Drug Administration ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

(ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...